Fig. 3

5-year overall survival (OS) and 5-year breast cancer -specific (BCSS) for hormone receptor-positive female breast cancer patients between 1990 and 2014. (A)OS; (B)BCSS. Note: Inserts show FDA approvals of various endocrine therapy and targeted therapy agents for treatment of hormone receptor-positive tumors.